Terms: = Lung cancer AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Prognosis
16 results:
1. The necroptosis signature and molecular mechanism of lung squamous cell carcinoma.
Song GQ; Wu HM; Ji KJ; He TL; Duan YM; Zhang JW; Hu GQ
Aging (Albany NY); 2023 Nov; 15(22):12907-12926. PubMed ID: 37976123
[TBL] [Abstract] [Full Text] [Related]
2. Integration analysis using bioinformatics and experimental validation on the clinical and biological significance of TSLP in cancers.
Qu H; Liu X; Jiang T; Huang G; Cai H; Xing D; Mao Y; Zheng X
Cell Signal; 2023 Nov; 111():110874. PubMed ID: 37640192
[TBL] [Abstract] [Full Text] [Related]
3. Effects of Vitexin, a Natural Flavonoid Glycoside, on the Proliferation, Invasion, and Apoptosis of Human U251 Glioblastoma Cells.
Huang J; Zhou Y; Zhong X; Su F; Xu L
Oxid Med Cell Longev; 2022; 2022():3129155. PubMed ID: 35281458
[TBL] [Abstract] [Full Text] [Related]
4. KIAA1217 Promotes Epithelial-Mesenchymal Transition and Hepatocellular Carcinoma Metastasis by Interacting with and Activating STAT3.
Wang Y; Li N; Zheng Y; Wang A; Yu C; Song Z; Wang S; Sun Y; Zheng L; Wang G; Liu L; Yi J; Huang Y; Zhang M; Bao Y; Sun L
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008530
[TBL] [Abstract] [Full Text] [Related]
5. The expression landscape of jak1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC.
Shen K; Wei Y; Lv T; Song Y; Jiang X; Lu Z; Zhan P; Wang X; Fan M; Lu W
BMC Bioinformatics; 2021 Sep; 22(1):471. PubMed ID: 34587898
[TBL] [Abstract] [Full Text] [Related]
6. TYK2 is a prognostic biomarker and associated with immune infiltration in the lung adenocarcinoma microenvironment.
He A; Zhang R; Wang J; Huang Z; Liao W; Li Y; Wang C; Yang J; Feng Q; Wu L
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e129-e140. PubMed ID: 33852776
[TBL] [Abstract] [Full Text] [Related]
7. Decreased expression of jak1 associated with immune infiltration and poor prognosis in lung adenocarcinoma.
Cai J; Deng H; Luo L; You L; Liao H; Zheng Y
Aging (Albany NY); 2020 Dec; 13(2):2073-2088. PubMed ID: 33323549
[TBL] [Abstract] [Full Text] [Related]
8. [Severe MDA5 dermatomyositis associated with cancer and controlled by JAK inhibitor].
Jalles C; Deroux A; Tardieu M; Lugosi M; Viel S; Benveniste O; Colombe B
Rev Med Interne; 2020 Jun; 41(6):421-424. PubMed ID: 32192753
[TBL] [Abstract] [Full Text] [Related]
9. The IκB Kinase Inhibitor ACHP Targets the STAT3 Signaling Pathway in Human Non-Small Cell lung Carcinoma Cells.
Lee JH; Mohan CD; Basappa S; Rangappa S; Chinnathambi A; Alahmadi TA; Alharbi SA; Kumar AP; Sethi G; Ahn KS; Rangappa KS
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31847229
[TBL] [Abstract] [Full Text] [Related]
10. LncRNA ATB promotes proliferation and metastasis in A549 cells by down-regulation of microRNA-494.
Cao Y; Luo X; Ding X; Cui S; Guo C
J Cell Biochem; 2018 Aug; 119(8):6935-6942. PubMed ID: 29693289
[TBL] [Abstract] [Full Text] [Related]
11. A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell lung cancer and Systemic Inflammation.
Giaccone G; Sanborn RE; Waqar SN; Martinez-Marti A; Ponce S; Zhen H; Kennealey G; Erickson-Viitanen S; Schaefer E
Clin Lung Cancer; 2018 Sep; 19(5):e567-e574. PubMed ID: 29681434
[TBL] [Abstract] [Full Text] [Related]
12. jak1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell lung cancer.
Shien K; Papadimitrakopoulou VA; Ruder D; Behrens C; Shen L; Kalhor N; Song J; Lee JJ; Wang J; Tang X; Herbst RS; Toyooka S; Girard L; Minna JD; Kurie JM; Wistuba II; Izzo JG
Mol Cancer Ther; 2017 Oct; 16(10):2234-2245. PubMed ID: 28729401
[TBL] [Abstract] [Full Text] [Related]
13. Correlation of EGFR Del 19 with Fn14/JAK/STAT signaling molecules in non-small cell lung cancer.
Sun Y; Han Y; Wang X; Wang W; Wang X; Wen M; Xia J; Xing H; Li X; Zhang Z
Oncol Rep; 2016 Aug; 36(2):1030-40. PubMed ID: 27350337
[TBL] [Abstract] [Full Text] [Related]
14. Positive feedback regulation between IL10 and EGFR promotes lung cancer formation.
Hsu TI; Wang YC; Hung CY; Yu CH; Su WC; Chang WC; Hung JJ
Oncotarget; 2016 Apr; 7(15):20840-54. PubMed ID: 26956044
[TBL] [Abstract] [Full Text] [Related]
15. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic cancer for Whom Therapy With Gemcitabine Has Failed.
Hurwitz HI; Uppal N; Wagner SA; Bendell JC; Beck JT; Wade SM; Nemunaitis JJ; Stella PJ; Pipas JM; Wainberg ZA; Manges R; Garrett WM; Hunter DS; Clark J; Leopold L; Sandor V; Levy RS
J Clin Oncol; 2015 Dec; 33(34):4039-47. PubMed ID: 26351344
[TBL] [Abstract] [Full Text] [Related]
16. The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo.
Lee JH; Park KS; Alberobello AT; Kallakury B; Weng MT; Wang Y; Giaccone G
Clin Cancer Res; 2013 Dec; 19(24):6777-86. PubMed ID: 24158701
[TBL] [Abstract] [Full Text] [Related]
